PET imaging allows for the monitoring of vital pathophysiological changes in COVID-19 at the molecular level, providing critical guidance for subsequent COVID-19 diagnosis, evaluation, and treatment. The most commonly used PET imaging agent in COVID-19 cases is F-labeled fluorodeoxyglucose (18F-FDG), a radiolabeled glucose analogue, and the integrated PET/CT system can be used to characterise both the functional and structural changes of COVID-19 at the same time. This application of devices in the diagnosis and evaluation of the COVID-19 aided the PET-CT scanner devices market in gaining a foothold.
COVID-19 had a relatively positive impact on the PET-CT Scanner Device Market. The increased use of PET-CT scan devices in the diagnosis, evaluation, and treatment of COVID-19 was attributed to this. Furthermore, cancer patients undergoing radiation therapy are at an increased risk of developing more severe disease. The demand for PET CT scanner devices is expected to rise as cancer patients are concerned about the COVID-19 effects on them, which has also impacted market growth.
For more details, visit- https://cmi-latestreportorientedblogs.blogspot.com/2022/08/size-share-trends-and-forecast-of-pet.html
